Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657527 | 0.91 | CYP1B1 (0.82) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL657528 | 0.91 | CYP1B1 (0.82) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL656220 | 0.91 | CYP3A4 (0.77) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL656219 | 0.91 | CYP3A4 (0.77) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL29624424 | 0.91 | CYP3A4 (0.77) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL656428 | 0.87 | CYP1B1 (0.81) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL656427 | 0.87 | CYP1B1 (0.81) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL13680427 | 0.87 | CYP3A4 (0.75) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL25221764 | 0.86 | CYP3A4 (0.76) | CYP3A4PTPN1CYP1B1MAOAMAOB | |
| SCHEMBL15507014 | 0.86 | CYP3A4 (0.76) | CYP3A4PTPN1CYP1B1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | CYP3A4 1342/4885PTPN1 395/4885CYP1B1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.